Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bowman Cox

Executive Editor

Washington, DC
Bowman Cox leads the Pink Sheet's coverage of pharmaceutical manufacturing quality issues. He writes and edits articles on the challenges and opportunities that developments in science, technology and regulatory policy pose to drug manufacturers and their quality organizations.

Latest From Bowman Cox

NIIMBL Aims To Help Manufacturers Perfect Next-Generation COVID-19 Vaccines

Public-private partnership could help coronavirus vaccine developers increase thermal stability, strengthen potency assays and fine-tune adventitious agent testing, among other things.

Coronavirus COVID-19 Vaccines

Can 'Buy American’ Executive Order Shake Up ‘Dickensian’ Manufacturing Dynamics?

The Trump administration’s move to strengthen domestic manufacture of essential medicines raises a lot of questions – and industry’s ire.

Manufacturing Policy

BARDA Begins Stockpiling APIs For Critical Drugs

US agency ensures pharmaceutical companies could manufacture critical medicines domestically even if cut off from China's API suppliers, while stockpiling pandemic medicines during pandemic with Baxter, Fresenius contracts.

Coronavirus COVID-19 Ingredients

How BARDA Locked Up COVID-19 Vaccine Manufacturing Capacity For Operation Warp Speed

US agency avoided procurement delays with sole-source awards to two medical countermeasures venture partners worth nearly $900m.

Coronavirus COVID-19 Manufacturing

US DoJ Lets Biotechs Share Manufacturing Details To Speed Launch Of COVID-19 Therapies

Companies are shielded from antitrust concerns by Justice Department as they jointly prepare to manufacture whichever monoclonal-antibody-based coronavirus therapies emerge from development.

Coronavirus COVID-19 Manufacturing

How The European Medicines Agency Inspected Thermo Fisher’s Florida Plant Without Leaving Europe

Contract development and manufacturing organization relied on combination of immersive mixed-reality devices to host remote inspection.

Manufacturing Quality
See All
UsernamePublicRestriction

Register